Richard L. Theriault

Author

The University of Texas MD Anderson Cancer Center

Also Known As

E. Thiel, R L Theriault, R THERIAULT, R Theriault, R Thériault, R. L. Theriault, R. Theriault, R. Thériault, R.L Theriault, R.L. Theriault

312

Publications

28.5K

Citations

H-Index

110

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Dana-Farber Cancer Institute Breast Cancer Care Roswell Park Comprehensive Cancer Center Fox Chase Cancer Center

About

Richard L. Theriault is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, breast cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	36	65	4.3K
2	Health Sciences	18	21	1.2K
3	Public Health	5	5	273
4	Nursing	3	3	260
5	Language Studies	1	1	23

Richard L. Theriault

167

Publications

26.2K

Citations

H-Index

Page 1

	Year	Citations
Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy Henry M. Kuerer, Lisa A. Newman, Terry L. Smith, Journal of Clinical Oncology	1999	1.3K
Revision of the American Joint Committee on Cancer Staging System for Breast Cancer S. Eva Singletary, Craig Allred, Pandora Ashley, Journal of Clinical Oncology	2002	1.2K
Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer Aman U. Buzdar, Nuhad K. Ibrahim, Deborah Francis, Journal of Clinical Oncology	2005	1.2K
Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone Metastases Gabriel N. Hortobágyi, Richard L. Theriault, Lester Porter, New England Journal of Medicine	1996	1K
THE IMPACT OF NATIONAL CANCER ACT Frankie A. Holmes, Ronald S. Walters, Richard L. Theriault, JNCI Journal of the National Cancer Institute	1991	802
Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer Kenneth R. Hess, K. Anderson, W. Fraser Symmans, Journal of Clinical Oncology	2006	715
Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network Nancy U. Lin, Ann Vanderplas, Melissa E. Hughes, Cancer	2012	679
The cognitive sequelae of standard‐dose adjuvant chemotherapy in women with breast carcinoma Jeffrey S. Wefel, Renato Lenzi, Richard L. Theriault, Cancer	2004	676
Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. G. N. Hortobagyi, Richard L. Theriault, A. Lipton, Journal of Clinical Oncology	1998	631
Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Nuhad K. Ibrahim, Neil Desai, Sewa S. Legha, PubMed	2002	630

Page 1